Nonalcoholic Fatty Liver Disease and Liver Transplantation

Tuan Pham, Travis B. Dick, Michael R. Charlton

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is prevalent in the general population and a growing indication for liver transplant. Longer wait times and challenges with pretransplant survivorship are expected, underscoring the need for improved management of attendant comorbidities. Recognition with potentiwal modification of obesity, sarcopenia, chronic kidney disease, and cardiovascular disease in patients with NAFLD may have important implications in the pretransplant and posttransplant periods. Although patients with NAFLD have generally favorable postoperative outcomes, they are at risk for developing recurrent disease in their allograft, driving the need for pharmacotherapies and dietary innovations appropriate for use in the posttransplant period.

Original languageEnglish (US)
Pages (from-to)403-417
Number of pages15
JournalClinics in Liver Disease
Volume20
Issue number2
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Liver Transplantation
Sarcopenia
Chronic Renal Insufficiency
Allografts
Comorbidity
Cardiovascular Diseases
Survival Rate
Obesity
Transplants
Drug Therapy
Liver
Population
Non-alcoholic Fatty Liver Disease

Keywords

  • Liver transplantation
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis
  • The metabolic syndrome

ASJC Scopus subject areas

  • Hepatology

Cite this

Nonalcoholic Fatty Liver Disease and Liver Transplantation. / Pham, Tuan; Dick, Travis B.; Charlton, Michael R.

In: Clinics in Liver Disease, Vol. 20, No. 2, 01.05.2016, p. 403-417.

Research output: Contribution to journalArticle

Pham, Tuan ; Dick, Travis B. ; Charlton, Michael R. / Nonalcoholic Fatty Liver Disease and Liver Transplantation. In: Clinics in Liver Disease. 2016 ; Vol. 20, No. 2. pp. 403-417.
@article{caee0987b0414e1782fe1a80336dd89f,
title = "Nonalcoholic Fatty Liver Disease and Liver Transplantation",
abstract = "Nonalcoholic fatty liver disease (NAFLD) is prevalent in the general population and a growing indication for liver transplant. Longer wait times and challenges with pretransplant survivorship are expected, underscoring the need for improved management of attendant comorbidities. Recognition with potentiwal modification of obesity, sarcopenia, chronic kidney disease, and cardiovascular disease in patients with NAFLD may have important implications in the pretransplant and posttransplant periods. Although patients with NAFLD have generally favorable postoperative outcomes, they are at risk for developing recurrent disease in their allograft, driving the need for pharmacotherapies and dietary innovations appropriate for use in the posttransplant period.",
keywords = "Liver transplantation, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, The metabolic syndrome",
author = "Tuan Pham and Dick, {Travis B.} and Charlton, {Michael R.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.cld.2015.10.014",
language = "English (US)",
volume = "20",
pages = "403--417",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Nonalcoholic Fatty Liver Disease and Liver Transplantation

AU - Pham, Tuan

AU - Dick, Travis B.

AU - Charlton, Michael R.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Nonalcoholic fatty liver disease (NAFLD) is prevalent in the general population and a growing indication for liver transplant. Longer wait times and challenges with pretransplant survivorship are expected, underscoring the need for improved management of attendant comorbidities. Recognition with potentiwal modification of obesity, sarcopenia, chronic kidney disease, and cardiovascular disease in patients with NAFLD may have important implications in the pretransplant and posttransplant periods. Although patients with NAFLD have generally favorable postoperative outcomes, they are at risk for developing recurrent disease in their allograft, driving the need for pharmacotherapies and dietary innovations appropriate for use in the posttransplant period.

AB - Nonalcoholic fatty liver disease (NAFLD) is prevalent in the general population and a growing indication for liver transplant. Longer wait times and challenges with pretransplant survivorship are expected, underscoring the need for improved management of attendant comorbidities. Recognition with potentiwal modification of obesity, sarcopenia, chronic kidney disease, and cardiovascular disease in patients with NAFLD may have important implications in the pretransplant and posttransplant periods. Although patients with NAFLD have generally favorable postoperative outcomes, they are at risk for developing recurrent disease in their allograft, driving the need for pharmacotherapies and dietary innovations appropriate for use in the posttransplant period.

KW - Liver transplantation

KW - Nonalcoholic fatty liver disease

KW - Nonalcoholic steatohepatitis

KW - The metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84962492077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962492077&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2015.10.014

DO - 10.1016/j.cld.2015.10.014

M3 - Article

AN - SCOPUS:84962492077

VL - 20

SP - 403

EP - 417

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 2

ER -